A Phase 3 interventional study of Mesorectal excision with lateral lymph node dissection and Mesorectal excision without lateral lymph node excision in Rectal Neoplasms, sponsored by Haruhiko Fukuda. Completed at 48 sites in Japan. Open to participants aged 21 Years to 74 Years. Per ClinicalTrials.gov, last updated 2016-09-22.
Sponsored by Haruhiko Fukuda · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 26 studies in Rectal Neoplasms with a site in Japan — 7 open to participants now, 12 under way, 5 of them phase 3. Rectal Neoplasms · Japan.
Among the 26 studies in Rectal Neoplasms with a site in Japan, this one is the 4th largest by enrollment of the 24 interventional ones that give a count, is the only one that started in 2003, is one of 8 in phase 3, and was the 1st registered.
2,403 studies on the registry are indexed under Rectal Neoplasms; 588 are open to participants now.
Browse Rectal Neoplasms studies →7 of the 26 studies in Rectal Neoplasms with a site in Japan are open now. Recruiting first, the newest first:
GlaxoSmithKline · Sites in Japan, United States, Canada and 6 more countries
Ages 18+
Merck Sharp & Dohme LLC · Sites in Japan, United States, Argentina and 26 more countries
Ages 18+
Osaka University · Sites in Japan
Ages 18+
City of Hope Medical Center · Sites in Japan, United States, Italy and 1 more country
Ages 18–50 · Healthy volunteers
National Cancer Center Hospital East · Sites in Japan
Ages 18+
A study can be open while its sites in Japan have not opened yet or have stopped. Only those recruiting at a site in Japan →
Of the 404 Rectal Neoplasms studies recruiting now, 209 (52%) set no upper age limit and 143 (35%) stop at 75 or younger; 19 take children under 18; 16 take healthy volunteers.
This study: 21 Years to 74 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
26 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 9 · Phase 2 12 · Phase 3 8
First in 2003; this study’s year is marked. 1 started in 2003.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 700 is above the median of 65 across 1,754 interventional studies indexed under Rectal Neoplasms.
Median enrollment 105 across the 24 interventional studies, 756 across the 2 observational. Of the 7 that completed or were terminated, 1 (14%) have results posted.
This tab as a report to print or save as PDF → With an account.
9 of 26 have an industry lead sponsor. The 10 most frequent:
Haruhiko Fukuda is the lead sponsor of 13 studies on the registry; none are open to participants now.
Haruhiko Fukuda has 1 study filed under Rectal Neoplasms — fewer than ten, so there is no comparison to draw.
1 of the studies in Rectal Neoplasms with a site in Japan that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05544929Novartis PharmaceuticalsA Study of Safety and Efficacy of KFA115 Alone and in Combo With Pembrolizumab in Patients With Select Advanced Cancers | 2027-10-05 |
Add it to your calendar (.ics) → With an account.
Among the 26 studies in Rectal Neoplasms with a site in Japan, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the of international standard operation, mesorectal excision (ME alone) compared to Japanese standard operation, ME with lateral lymph node dissection for clinical stage II, III lower rectal cancer
Total mesorectal excision (TME) or mesorectal excision (ME) with lateral lymph node dissection for advanced rectal cancer is widely performed in Japan. In other countries, TME or ME without lateral lymph node dissection is the standard. In order to determine which is the better rectal cancer surgery, relapse-free survivals of these are compared as the primary endpoint.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Preoperative criteria:
Preoperative findings:
Written
Operative criteria:
Operative findings:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Procedure/Surgery: Mesorectal excision with lateral lymph node dissection
Procedure: Mesorectal excision with lateral lymph node dissection
Procedure/Surgery: Mesorectal excision without lateral lymph node excision
Procedure: Mesorectal excision without lateral lymph node excision
Mesorectal excision with lateral lymph node dissection
Mesorectal excision without lateral lymph node excision
Relapse-free survival
Time frame: Until relapsing
Overall survival
Time frame: Overall
Local-recurrence-free survival
Time frame: Until local-recurrence
Incidence of adverse events
Time frame: 5 years
Incidence of major adverse events
Time frame: 5 years
Operative time
Time frame: Operation day
Blood loss
Time frame: Operation day
Incidence of sexual and urinary dysfunction
Time frame: 1 year
The record gives a start of Jun 2003, a primary completion of Jun 2015 and a completion of Jun 2015. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Haruhiko Fukuda